Bielefeld M R, Bishop D A, Campbell D N, Mitchell M B, Grover F L, Clarke D R
Division of Cardiothoracic Surgery, University of Colorado Health Sciences Center, and The Children's Hospital, Denver, USA.
Ann Thorac Surg. 2001 Feb;71(2):482-7; discussion 487-8. doi: 10.1016/s0003-4975(00)02521-2.
Homografts are implanted in the right ventricular outflow tract (RVOT) of children, with the knowledge that reoperation might be required. We reviewed 14 years of homograft RVOT reconstruction to assess the feasibility of homograft replacement and to determine risk factors for homograft survival.
From February 1985 through March 1999, 223 children (age 5 days to 16.9 years) underwent primary RVOT reconstruction with an aortic or pulmonary homograft. Of these, 35 patients underwent homograft explant at the implanting hospital with insertion of a second homograft from 2 months to 13.3 years after the first implantation. The primary operation and reoperation patient groups were compared with regard to incidence of early death, late death, homograft-related intervention without explant, and homograft explant.
Actuarial survival and event-free curves for initial and replacement homografts were not significantly different. Univariable analysis was performed for the following risk factors: weight (p < 0.0001), age (p < 0.003), homograft diameter (p < 0.0001), homograft type (p < 0.01), surgery date (not significant [NS]), gender (NS), Blood Group match (NS), and type of distal anastomosis (NS). Multivariable analysis of significant univariable risks revealed small homograft diameter to be a significant risk factor (p < 0.001) for replacement.
The RVOT homografts eventually require replacement. Patient and homograft survival for replacement homografts is similar to primary homografts. Reoperative homograft RVOT reconstruction is possible, with reasonably low morbidity and mortality.
已知儿童右心室流出道(RVOT)植入同种异体移植物后可能需要再次手术。我们回顾了14年的同种异体移植物RVOT重建情况,以评估同种异体移植物置换的可行性,并确定同种异体移植物存活的危险因素。
从1985年2月至1999年3月,223名儿童(年龄5天至16.9岁)接受了主动脉或肺动脉同种异体移植物的初次RVOT重建。其中,35例患者在植入医院接受了同种异体移植物取出术,并在首次植入后2个月至13.3年植入了第二个同种异体移植物。比较初次手术和再次手术患者组在早期死亡、晚期死亡、未取出移植物的同种异体移植物相关干预以及同种异体移植物取出方面的发生率。
初次和置换同种异体移植物的精算生存率和无事件曲线无显著差异。对以下危险因素进行单变量分析:体重(p<0.0001)、年龄(p<0.003)、同种异体移植物直径(p<0.0001)、同种异体移植物类型(p<0.01)、手术日期(无显著性差异[NS])、性别(NS)、血型匹配(NS)和远端吻合类型(NS)。对显著的单变量风险进行多变量分析显示,同种异体移植物直径小是置换的一个显著危险因素(p<0.001)。
RVOT同种异体移植物最终需要置换。置换同种异体移植物的患者和移植物存活率与初次同种异体移植物相似。再次进行同种异体移植物RVOT重建是可行的,发病率和死亡率较低。